Mohamed Saleh Elgawish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed Saleh Elgawish has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Naoya Kishikawa
Department of Analytical Chemistry for Pharmaceutics, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan
7 shared publications Samia M. Mostafa
Medicinal Chemistry Department, Faculty of Pharmacy
7 shared publications- Naotaka Kuroda
Department of Analytical Chemistry for Pharmaceuticals, Course of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan
5 shared publications Abdalla A. Elshanawane
Medicinal Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
4 shared publications- Mohamed Shaban Nafie
Department of Chemistry, College of Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates
4 shared publications - Ranza Elrayess
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt
4 shared publications
Latest Publications
- 12 August 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (10) , 4698-4720
Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects
Protein kinases are central regulators of cell signaling and play pivotal roles in a wide array of diseases, most notably cancer and autoimmune disorders. The clinical success of kinase inhibitors—such as imatinib and osimertinib—has firmly established kinases as valuable drug targets. However, the development of selective, potent inhibitors remains challenging due to the conserved nature of the ATP-binding site, off-target effects, resistance mutations, and patient-specific variability. Recent advances in artificial intelligence (AI) and machine learning (ML) offer transformative solutions to these obstacles across the drug discovery pipeline. This review explores how AI/ML methods, including deep learning, graph neural networks, and generative models, are revolutionizing the design, optimization, and repurposing of kinase inhibitors. We detail applications in target identification, virtual screening, structure–activity relationship modeling, resistance prediction, and clinical trial design. Representative case studies—such as AI-optimized BTK and EGFR inhibitors—highlight real-world impact. We also examine current limitations, including data sparsity, model interpretability, and translational gaps between in silico and experimental results. Finally, we discuss emerging directions such as federated learning, personalized kinase inhibitors, and AI-enabled combination therapies. By integrating computational innovation with medicinal chemistry, AI/ML holds immense promise to accelerate and refine the next generation of kinase-targeted therapeutics.
- 12 August 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (10) , 4698-4720
Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects
Protein kinases are central regulators of cell signaling and play pivotal roles in a wide array of diseases, most notably cancer and autoimmune disorders. The clinical success of kinase inhibitors—such as imatinib and osimertinib—has firmly established kinases as valuable drug targets. However, the development of selective, potent inhibitors remains challenging due to the conserved nature of the ATP-binding site, off-target effects, resistance mutations, and patient-specific variability. Recent advances in artificial intelligence (AI) and machine learning (ML) offer transformative solutions to these obstacles across the drug discovery pipeline. This review explores how AI/ML methods, including deep learning, graph neural networks, and generative models, are revolutionizing the design, optimization, and repurposing of kinase inhibitors. We detail applications in target identification, virtual screening, structure–activity relationship modeling, resistance prediction, and clinical trial design. Representative case studies—such as AI-optimized BTK and EGFR inhibitors—highlight real-world impact. We also examine current limitations, including data sparsity, model interpretability, and translational gaps between in silico and experimental results. Finally, we discuss emerging directions such as federated learning, personalized kinase inhibitors, and AI-enabled combination therapies. By integrating computational innovation with medicinal chemistry, AI/ML holds immense promise to accelerate and refine the next generation of kinase-targeted therapeutics.
- Open Access
- 1 April 2025
- Published by Egyptian Knowledge Bank in Egyptian Pharmaceutical Journal
- Vol. 24 (2) , 152-170
Innovations in acetylcholinesterase inhibitors: emerging strategies for Alzheimer’s disease therapy (2019–2024)
Alzheimer’s disease (AD) is a prevalent irreversible neurological degenerative disorder and one of the considerable health hazards in the aged population worldwide. It is estimated that AD population will reach 74.4 million by 2030, and the prevalence is anticipated to reach 131.5 million by 2050, representing an enormous burden on health organizations. AD is a familiar type of dementia characterized by gradual memory loss and cognitive function impairment. AD is a complex multifactorial disease, and the cholinergic hypothesis is the primary theory explaining its pathogenesis. It was observed that the brains of AD patients showed a sharp decrease in cholinergic neurons and a remarkable deficiency in acetylcholine levels. Thus, acetylcholinesterase inhibitors (AChEI) are considered a promising strategy for AD treatment. The FDA approves four AChEI for AD treatment: tacrine, donepezil, rivastigmine, and galantamine. This review article focuses on the latest advances in the development of new AChEI inhibitors from 2019 to 2024, encompassing single-targeted, multi-targeted, and naturally derived inhibitors as potential treatments for AD. It highlights new molecules with promising inhibitory activity against acetylcholinesterase, underscoring their therapeutic potential in AD management.
- 1 April 2025
- Published by Egyptian Knowledge Bank in Egyptian Pharmaceutical Journal
- Vol. 24 (2) , 152-170
Open AccessInnovations in acetylcholinesterase inhibitors: emerging strategies for Alzheimer’s disease therapy (2019–2024)
Alzheimer’s disease (AD) is a prevalent irreversible neurological degenerative disorder and one of the considerable health hazards in the aged population worldwide. It is estimated that AD population will reach 74.4 million by 2030, and the prevalence is anticipated to reach 131.5 million by 2050, representing an enormous burden on health organizations. AD is a familiar type of dementia characterized by gradual memory loss and cognitive function impairment. AD is a complex multifactorial disease, and the cholinergic hypothesis is the primary theory explaining its pathogenesis. It was observed that the brains of AD patients showed a sharp decrease in cholinergic neurons and a remarkable deficiency in acetylcholine levels. Thus, acetylcholinesterase inhibitors (AChEI) are considered a promising strategy for AD treatment. The FDA approves four AChEI for AD treatment: tacrine, donepezil, rivastigmine, and galantamine. This review article focuses on the latest advances in the development of new AChEI inhibitors from 2019 to 2024, encompassing single-targeted, multi-targeted, and naturally derived inhibitors as potential treatments for AD. It highlights new molecules with promising inhibitory activity against acetylcholinesterase, underscoring their therapeutic potential in AD management.
- 19 March 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (4) , 1116-1128
Revealing Pharmacokinetic Interactions of Tramadol, Tapentadol, and Venlafaxine: A Cutting-Edge Liquid Chromatography–Tandem Mass Spectrometry Analytical Approach in Rat Plasma
The detection and quantification of opioid analgesics adulterated with serotonin reuptake inhibitors are critical in forensic toxicology due to their significant clinical and legal implications. This study focuses on developing and validating a highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of tramadol (TMD), tapentadol (TAP), and venlafaxine (VEN) in small volumes of rat plasma. The method employs a straightforward single-step protein precipitation technique for sample pretreatment. Utilizing a Shim-pack Velox SP-C18 column (2.7 μm, 2.1 × 150 mm, Shimadzu, Japan), a 12 min gradient elution was performed with a mobile phase of 0.1% formic acid in water (solvent A) and acetonitrile (solvent B). Detection and quantification were achieved in multiple-reaction-monitoring mode, with ion transitions of m/z 264.3 → 58.1 for TMD, m/z 222.3 → 107.1 for TAP, m/z 278.2 → 58.2 for VEN, and m/z 195.5 → 138.1 for caffeine, which served as the internal standard (IS). The method exhibited excellent linearity, with concentration ranges of 1-500 ng/mL for TMD (r 2 = 0.9981), 1-1000 ng/mL for TAP (r 2 = 0.9972), and 1-900 ng/mL for VEN (r 2 = 0.9987) in rat plasma using only 50 μL of sample. This validated method was applied to a pharmacokinetic interaction study, revealing significant drug interactions: the maximum observed plasma concentration (C max) and area under the curve (AUC) for both TMD and VEN decreased. For TMD, C max decreased by 2.58-fold from 276.25 to 106.99, and AUC0-t decreased by 1.4-fold from 3005.8 to 2159.3. For VEN, C max decreased by 2.51-fold from 494 to 191, and AUC0-t decreased by 2.3-fold from 4988 to 2114. However, for TAP, C max increased by 3.4-fold from 138.54 to 471.85, and AUC0-t increased by 2.66-fold from 1060.1 to 2826.8. The concurrent administration likely creates metabolic competition at CYP2D6 and UDP glycosyltransferase enzyme sites, affecting the pharmacokinetic parameters. These findings underscore the importance of further studies to monitor the simultaneous presence of these drugs and their metabolites in plasma, especially when coadministration occurs unintentionally.
- 19 March 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (4) , 1116-1128
Revealing Pharmacokinetic Interactions of Tramadol, Tapentadol, and Venlafaxine: A Cutting-Edge Liquid Chromatography–Tandem Mass Spectrometry Analytical Approach in Rat Plasma
The detection and quantification of opioid analgesics adulterated with serotonin reuptake inhibitors are critical in forensic toxicology due to their significant clinical and legal implications. This study focuses on developing and validating a highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of tramadol (TMD), tapentadol (TAP), and venlafaxine (VEN) in small volumes of rat plasma. The method employs a straightforward single-step protein precipitation technique for sample pretreatment. Utilizing a Shim-pack Velox SP-C18 column (2.7 μm, 2.1 × 150 mm, Shimadzu, Japan), a 12 min gradient elution was performed with a mobile phase of 0.1% formic acid in water (solvent A) and acetonitrile (solvent B). Detection and quantification were achieved in multiple-reaction-monitoring mode, with ion transitions of m/z 264.3 → 58.1 for TMD, m/z 222.3 → 107.1 for TAP, m/z 278.2 → 58.2 for VEN, and m/z 195.5 → 138.1 for caffeine, which served as the internal standard (IS). The method exhibited excellent linearity, with concentration ranges of 1-500 ng/mL for TMD (r 2 = 0.9981), 1-1000 ng/mL for TAP (r 2 = 0.9972), and 1-900 ng/mL for VEN (r 2 = 0.9987) in rat plasma using only 50 μL of sample. This validated method was applied to a pharmacokinetic interaction study, revealing significant drug interactions: the maximum observed plasma concentration (C max) and area under the curve (AUC) for both TMD and VEN decreased. For TMD, C max decreased by 2.58-fold from 276.25 to 106.99, and AUC0-t decreased by 1.4-fold from 3005.8 to 2159.3. For VEN, C max decreased by 2.51-fold from 494 to 191, and AUC0-t decreased by 2.3-fold from 4988 to 2114. However, for TAP, C max increased by 3.4-fold from 138.54 to 471.85, and AUC0-t increased by 2.66-fold from 1060.1 to 2826.8. The concurrent administration likely creates metabolic competition at CYP2D6 and UDP glycosyltransferase enzyme sites, affecting the pharmacokinetic parameters. These findings underscore the importance of further studies to monitor the simultaneous presence of these drugs and their metabolites in plasma, especially when coadministration occurs unintentionally.
- 9 November 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (12) , 4032-4042
Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Citalopram and Duloxetine: An Integrated Analytical, Computational, Behavioral, and Biochemical Approach
Despite the prevalent utilization of antidepressant combinations in clinical settings, concerns persist regarding heightened side effects and potential drug-drug interactions (DDI). In response, this study investigates the interaction between citalopram (CIT) and duloxetine (DUL) using a multifaceted approach encompassing analytical, computational, behavioral, and biochemical techniques. Notably, the absence of published analytical methods tailored for studying antidepressant interactions underscores the novelty of our endeavor. We present the development and validation of a robust and sensitive assay, coupling liquid chromatography-tandem mass spectrometry. This method facilitates the simultaneous determination of DUL, a serotonin-norepinephrine reuptake inhibitor (SNRI), and CIT, a selective serotonin reuptake inhibitor (SSRI), in rat plasma following oral administration. Successful pharmacokinetic and DDI monitoring of DUL and CIT in rat plasma post a single oral dose of 120 mg/kg is achieved using this method. Our findings reveal DUL's influence on CIT's pharmacokinetic parameters, resulting in an increased area under the concentration-time curve (AUC) by 4-fold, peak plasma concentrations (C max) by 20-fold, maximum plasma concentration-time (T max) by 4-fold, and oral clearance (Cl/F) of CIT by 1.3-fold upon coadministration. Furthermore, our investigation explores the behavioral and biochemical ramifications of coadministering CIT and DUL through the sucrose preference test (SPT), forced swimming test (FST), and enzyme-linked immunosorbent assay (ELISA). We observe potential exacerbation of serotonin concentration and serotonin syndrome in rat models. Molecular modeling studies indicate that DUL may competitively inhibit CYP2D6, the principal enzyme responsible for CIT metabolism, as well as P-glycoprotein (P-gp), which extrudes CIT back to the intestinal lumen. These findings emphasize the imperative of further research into potential DDIs in psychiatric patients undergoing chronic treatment with DUL and CIT to mitigate adverse effects and serotonin syndrome.
- 9 November 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (12) , 4032-4042
Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Citalopram and Duloxetine: An Integrated Analytical, Computational, Behavioral, and Biochemical Approach
Despite the prevalent utilization of antidepressant combinations in clinical settings, concerns persist regarding heightened side effects and potential drug-drug interactions (DDI). In response, this study investigates the interaction between citalopram (CIT) and duloxetine (DUL) using a multifaceted approach encompassing analytical, computational, behavioral, and biochemical techniques. Notably, the absence of published analytical methods tailored for studying antidepressant interactions underscores the novelty of our endeavor. We present the development and validation of a robust and sensitive assay, coupling liquid chromatography-tandem mass spectrometry. This method facilitates the simultaneous determination of DUL, a serotonin-norepinephrine reuptake inhibitor (SNRI), and CIT, a selective serotonin reuptake inhibitor (SSRI), in rat plasma following oral administration. Successful pharmacokinetic and DDI monitoring of DUL and CIT in rat plasma post a single oral dose of 120 mg/kg is achieved using this method. Our findings reveal DUL's influence on CIT's pharmacokinetic parameters, resulting in an increased area under the concentration-time curve (AUC) by 4-fold, peak plasma concentrations (C max) by 20-fold, maximum plasma concentration-time (T max) by 4-fold, and oral clearance (Cl/F) of CIT by 1.3-fold upon coadministration. Furthermore, our investigation explores the behavioral and biochemical ramifications of coadministering CIT and DUL through the sucrose preference test (SPT), forced swimming test (FST), and enzyme-linked immunosorbent assay (ELISA). We observe potential exacerbation of serotonin concentration and serotonin syndrome in rat models. Molecular modeling studies indicate that DUL may competitively inhibit CYP2D6, the principal enzyme responsible for CIT metabolism, as well as P-glycoprotein (P-gp), which extrudes CIT back to the intestinal lumen. These findings emphasize the imperative of further research into potential DDIs in psychiatric patients undergoing chronic treatment with DUL and CIT to mitigate adverse effects and serotonin syndrome.
- 29 April 2024
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 37 (5) , 779-790
Unveiling Pharmacokinetics and Drug Interaction of Linagliptin and Pioglitazone HCl in Rat Plasma Using LC-MS/MS
The linagliptin (LIN) and pioglitazone HCl (PIO) combination, currently undergoing phase III clinical trials for diabetes mellitus treatment, demonstrated significant improvements in glycemic control. However, the absence of an analytical method for simultaneous determination in biological fluids highlights a crucial gap. This underscores the pressing need for sensitive bioanalytical methods, emphasizing the paramount importance of developing such tools to advance diabetes management strategies and enhance patient care. Herein, a sensitive reverse-phase high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry method was developed for simultaneous determination of LIN and PIO in rat plasma using alogliptin as an internal standard. Chromatographic separation was performed on an Agilent Eclipse Plus C18 (4.6 × 100 mm, 3.5 μm) using an isocratic mobile phase system consisting of ammonium formate (pH 4.5) and methanol using an acetonitrile-induced protein precipitation technique for sample preparation. Multiple reaction monitoring in positive ion mode was used for quantitation of the precursor to production at m/z 473.2 → 419.9 for LIN, 357.1 → 134.2 for PIO, and 340.3 → 116.1 for ALO. The linearity range was 0.5 to 100 and 1 to 2000 ng/mL for LIN and PIO, respectively. The developed method was validated as per US-FDA guidelines and successfully applied to clinical pharmacokinetic and drug-drug interaction studies with a single oral administration of LIN and PIO in rat plasma. Pharmacokinetic parameters of LIN were significantly influenced by the concomitant administration of PIO and vice versa. Molecular modeling revealed the significant interaction of LIN and PIO with P-glycoprotein. Therefore, the drug-drug interaction between LIN and PIO deserves further study to improve drug therapy and prevent dangerous adverse effects.
- 29 April 2024
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 37 (5) , 779-790
Unveiling Pharmacokinetics and Drug Interaction of Linagliptin and Pioglitazone HCl in Rat Plasma Using LC-MS/MS
The linagliptin (LIN) and pioglitazone HCl (PIO) combination, currently undergoing phase III clinical trials for diabetes mellitus treatment, demonstrated significant improvements in glycemic control. However, the absence of an analytical method for simultaneous determination in biological fluids highlights a crucial gap. This underscores the pressing need for sensitive bioanalytical methods, emphasizing the paramount importance of developing such tools to advance diabetes management strategies and enhance patient care. Herein, a sensitive reverse-phase high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry method was developed for simultaneous determination of LIN and PIO in rat plasma using alogliptin as an internal standard. Chromatographic separation was performed on an Agilent Eclipse Plus C18 (4.6 × 100 mm, 3.5 μm) using an isocratic mobile phase system consisting of ammonium formate (pH 4.5) and methanol using an acetonitrile-induced protein precipitation technique for sample preparation. Multiple reaction monitoring in positive ion mode was used for quantitation of the precursor to production at m/z 473.2 → 419.9 for LIN, 357.1 → 134.2 for PIO, and 340.3 → 116.1 for ALO. The linearity range was 0.5 to 100 and 1 to 2000 ng/mL for LIN and PIO, respectively. The developed method was validated as per US-FDA guidelines and successfully applied to clinical pharmacokinetic and drug-drug interaction studies with a single oral administration of LIN and PIO in rat plasma. Pharmacokinetic parameters of LIN were significantly influenced by the concomitant administration of PIO and vice versa. Molecular modeling revealed the significant interaction of LIN and PIO with P-glycoprotein. Therefore, the drug-drug interaction between LIN and PIO deserves further study to improve drug therapy and prevent dangerous adverse effects.
- 19 March 2024
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 243, 116109
Green innovation in analytical chemistry: A sustainable densitometric HPTLC approach for the distinctive separation and quantification of structurally related abused drugs - tramadol, tapentadol, and venlafaxine - in seized pharmaceutical dosage forms
- 19 March 2024
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 243, 116109
Green innovation in analytical chemistry: A sustainable densitometric HPTLC approach for the distinctive separation and quantification of structurally related abused drugs - tramadol, tapentadol, and venlafaxine - in seized pharmaceutical dosage forms
- Open Access
- 5 December 2023
- Published by IOP Publishing in Methods and Applications in Fluorescence
- Vol. 12 (1) , 015009
Novel fluorescence approach for trace quantification of levonorgestrel in breast milk based on click reaction with benzonitrofurazan azide (NBD-AZ)
Although the great importance of oral contraceptive agents in birth control, their existence in breast milk became a cause for concern, since infant exposure to these hormones is associated with many health problems. Consequentially, developing a sensitive bioanalytical method for monitoring their concentrations in breast milk is an urgent demand to examine the safety or the risk of these compounds on infants. Levonorgestrel is one of the most common contraceptive hormones under concern. Despite the high sensitivity of the fluorometric methods, detection of Levonorgestrel by them is confined because its structure does not exhibit any fluorescence. For the first time, we proposed a promising click fluorescent probe, 4-azido-7-nitrobenzoxadiazole to react with the alkyne group of Levonorgestrel, to give a highly fluorescent triazole derivative that exhibited strong signal at wavelength of 544 nm after excitation at 470 nm. Reaction parameters impacting the fluorescence were cautiously studied and optimized. The suggested approach has been successfully applied in Levonorgestrel estimation in breast milk samples with linearity of (0.4–80 ng.ml−1) and low detection limit of 0.12 ng.ml−1 without interferences from any biological components and with mean % recovery of 97.84 ± 2.73. Accuracy, sensitivity, selectivity, simplicity, and low-cost makes this approach a convincing, promising, and appealing alternative over reported analytical methods for Levonorgestrel bioanalysis in different matrices.
- 5 December 2023
- Published by IOP Publishing in Methods and Applications in Fluorescence
- Vol. 12 (1) , 015009
Open AccessNovel fluorescence approach for trace quantification of levonorgestrel in breast milk based on click reaction with benzonitrofurazan azide (NBD-AZ)
Although the great importance of oral contraceptive agents in birth control, their existence in breast milk became a cause for concern, since infant exposure to these hormones is associated with many health problems. Consequentially, developing a sensitive bioanalytical method for monitoring their concentrations in breast milk is an urgent demand to examine the safety or the risk of these compounds on infants. Levonorgestrel is one of the most common contraceptive hormones under concern. Despite the high sensitivity of the fluorometric methods, detection of Levonorgestrel by them is confined because its structure does not exhibit any fluorescence. For the first time, we proposed a promising click fluorescent probe, 4-azido-7-nitrobenzoxadiazole to react with the alkyne group of Levonorgestrel, to give a highly fluorescent triazole derivative that exhibited strong signal at wavelength of 544 nm after excitation at 470 nm. Reaction parameters impacting the fluorescence were cautiously studied and optimized. The suggested approach has been successfully applied in Levonorgestrel estimation in breast milk samples with linearity of (0.4–80 ng.ml−1) and low detection limit of 0.12 ng.ml−1 without interferences from any biological components and with mean % recovery of 97.84 ± 2.73. Accuracy, sensitivity, selectivity, simplicity, and low-cost makes this approach a convincing, promising, and appealing alternative over reported analytical methods for Levonorgestrel bioanalysis in different matrices.
- 31 March 2023
- Published by Wiley in Archiv der Pharmazie
- Vol. 356 (6) , e2200654
2‐Phenylquinazolin‐4(3H)‐one scaffold as newly designed, synthesized VEGFR‐2 allosteric inhibitors with potent cytotoxicity through apoptosis
New derivatives of 2‐phenylquinazolin‐4(3H)‐one were designed, synthesized, and biologically evaluated as potent allosteric kinase inhibitors with in situ cytotoxicity against MCF‐7 and HepG2 cells. Compounds 15 and 18 among the proposed compounds showed promising antiproliferative activity against MCF‐7 (IC50 = 1.35 µM) and HepG2 cells (IC50 = 3.24 µM), comparable to sorafenib, with IC50 values of 3.04, 2.93 µM, respectively, according to in situ cytotoxicity testing. Comparing compounds 15 and 18 to sorafenib, the in vitro VEGFR‐2 inhibitory activity displayed encouraging selective efficacy with IC50 values of 13, 67, and 30 nM, respectively. Results of VEGFR‐2 inhibition at various ATP concentrations proved that there was no statistically significant difference between the IC50 values, which improved the non‐ATP competitive binding. Compound 15 caused apoptotic breast cancer cell death with 55.11‐fold cell‐cycle arrest at the S‐phase, where it affected the apoptosis‐mediated genes through upregulating P53, Bax, caspases 3, 8, and 9 and downregulating the antiapoptotic gene Bcl‐2. A molecular docking study was conducted to confirm the binding of the designed compounds to the allosteric site of VEGFR‐2 in DFG‐out mode, leaving the ATP‐binding pocket unoccupied when superimposed to the pose of sorafenib. The designed molecules showed resealable binding affinity toward the DFG loop and the allosteric site. Hence, the 2‐phenylquinazolin‐4(3H)‐one derivative constitutes intriguing starting points for designing apoptotic‐inducing drugs.
- 31 March 2023
- Published by Wiley in Archiv der Pharmazie
- Vol. 356 (6) , e2200654
2‐Phenylquinazolin‐4(3H)‐one scaffold as newly designed, synthesized VEGFR‐2 allosteric inhibitors with potent cytotoxicity through apoptosis
New derivatives of 2‐phenylquinazolin‐4(3H)‐one were designed, synthesized, and biologically evaluated as potent allosteric kinase inhibitors with in situ cytotoxicity against MCF‐7 and HepG2 cells. Compounds 15 and 18 among the proposed compounds showed promising antiproliferative activity against MCF‐7 (IC50 = 1.35 µM) and HepG2 cells (IC50 = 3.24 µM), comparable to sorafenib, with IC50 values of 3.04, 2.93 µM, respectively, according to in situ cytotoxicity testing. Comparing compounds 15 and 18 to sorafenib, the in vitro VEGFR‐2 inhibitory activity displayed encouraging selective efficacy with IC50 values of 13, 67, and 30 nM, respectively. Results of VEGFR‐2 inhibition at various ATP concentrations proved that there was no statistically significant difference between the IC50 values, which improved the non‐ATP competitive binding. Compound 15 caused apoptotic breast cancer cell death with 55.11‐fold cell‐cycle arrest at the S‐phase, where it affected the apoptosis‐mediated genes through upregulating P53, Bax, caspases 3, 8, and 9 and downregulating the antiapoptotic gene Bcl‐2. A molecular docking study was conducted to confirm the binding of the designed compounds to the allosteric site of VEGFR‐2 in DFG‐out mode, leaving the ATP‐binding pocket unoccupied when superimposed to the pose of sorafenib. The designed molecules showed resealable binding affinity toward the DFG loop and the allosteric site. Hence, the 2‐phenylquinazolin‐4(3H)‐one derivative constitutes intriguing starting points for designing apoptotic‐inducing drugs.
- Open Access
- 22 April 2022
- Published by Springer Nature in Research Square
Simultaneous Determination of Paracetamol and Orphenadrine Citrate in Rat Plasma using LC–MS/MS Spectrometry Method: Pharmacokinetics and Drug-Drug Interaction Profile Studies
Herein, it is the first developed and fully validated LC-MS/MS method for simultaneous determination of paracetamol (PAR) and orphenadrine citrate (ORP) in rat plasma after oral administration in respect of therapeutic drug monitoring, bioequivalence, pharmacokinetic (PK) and drug-drug interaction (DDI) studies. PAR and ORP were extracted from plasma sample using ACN-induced protein precipitation method. The separation procedure was carried out on an Agilent Eclipse Plus ODS (4.60 x 100 mm, 3.50 μm) column using water-enriched gradient mobile phase consisting of 6 mM ammonium formate plus 0.1% formic acid and ACN at a flow rate of 0.5 mL min-1. The mass spectrometry parameters were optimized and multiple reaction monitoring (MRM) in positive ion mode of two transitions was utilized for quantification of precursor to production at m/z 152 → 110 & 65 for PAR as [M+2H]2+, 270.3 → 181 for ORP as [M + H] +. According to US-FDA bioanalytical requirements, the proposed method was verified in terms of linearity, selectivity, recovery, accuracy, precision, matrix effects, and stability. The method was linear in the range of 1-5000 and 1-500 ng mL-1 with detection limits (S/N of 3) of 0.12 and 0.07 ng mL-1 for PAR and ORP, respectively. The selectivity and high sensitivity of the method succeeded in the study of PK parameters and DDI between PAR and ORP after oral dose administration. The synergistic action between the two drugs was confirmed by studying variable parameters like Ka, Tmax, Cmax, AUC0-24, MRT, and Cl/F. PAR affects the absorption of ORP and decreases its Cmax but increases its Tmax in accordance with elevating AUC0–24 and reducing Cl/F for both drugs. The current PK research is a useful tool for determining the DDI of both medicines and might be used in therapeutic drug monitoring and bioequivalence studies.
- 22 April 2022
- Published by Springer Nature in Research Square
Open AccessSimultaneous Determination of Paracetamol and Orphenadrine Citrate in Rat Plasma using LC–MS/MS Spectrometry Method: Pharmacokinetics and Drug-Drug Interaction Profile Studies
Herein, it is the first developed and fully validated LC-MS/MS method for simultaneous determination of paracetamol (PAR) and orphenadrine citrate (ORP) in rat plasma after oral administration in respect of therapeutic drug monitoring, bioequivalence, pharmacokinetic (PK) and drug-drug interaction (DDI) studies. PAR and ORP were extracted from plasma sample using ACN-induced protein precipitation method. The separation procedure was carried out on an Agilent Eclipse Plus ODS (4.60 x 100 mm, 3.50 μm) column using water-enriched gradient mobile phase consisting of 6 mM ammonium formate plus 0.1% formic acid and ACN at a flow rate of 0.5 mL min-1. The mass spectrometry parameters were optimized and multiple reaction monitoring (MRM) in positive ion mode of two transitions was utilized for quantification of precursor to production at m/z 152 → 110 & 65 for PAR as [M+2H]2+, 270.3 → 181 for ORP as [M + H] +. According to US-FDA bioanalytical requirements, the proposed method was verified in terms of linearity, selectivity, recovery, accuracy, precision, matrix effects, and stability. The method was linear in the range of 1-5000 and 1-500 ng mL-1 with detection limits (S/N of 3) of 0.12 and 0.07 ng mL-1 for PAR and ORP, respectively. The selectivity and high sensitivity of the method succeeded in the study of PK parameters and DDI between PAR and ORP after oral dose administration. The synergistic action between the two drugs was confirmed by studying variable parameters like Ka, Tmax, Cmax, AUC0-24, MRT, and Cl/F. PAR affects the absorption of ORP and decreases its Cmax but increases its Tmax in accordance with elevating AUC0–24 and reducing Cl/F for both drugs. The current PK research is a useful tool for determining the DDI of both medicines and might be used in therapeutic drug monitoring and bioequivalence studies.
- Open Access
- 27 January 2022
- Published by Wiley in Advanced Science
- Vol. 9 (9) , 2101817
Bleaching‐Resistant Super‐Resolution Fluorescence Microscopy
Photobleaching is the permanent loss of fluorescence after extended exposure to light and is a major limiting factor in super‐resolution microscopy (SRM) that restricts spatiotemporal resolution and observation time. Strategies for preventing or overcoming photobleaching in SRM are reviewed developing new probes and chemical environments. Photostabilization strategies are introduced first, which are borrowed from conventional fluorescence microscopy, that are employed in SRM. SRM‐specific strategies are then highlighted that exploit the on–off transitions of fluorescence, which is the key mechanism for achieving super‐resolution, which are becoming new routes to address photobleaching in SRM. Off states can serve as a shelter from excitation by light or an exit to release a damaged probe and replace it with a fresh one. Such efforts in overcoming the photobleaching limits are anticipated to enhance resolution to molecular scales and to extend the observation time to physiological lifespans.
- 27 January 2022
- Published by Wiley in Advanced Science
- Vol. 9 (9) , 2101817
Open AccessBleaching‐Resistant Super‐Resolution Fluorescence Microscopy
Photobleaching is the permanent loss of fluorescence after extended exposure to light and is a major limiting factor in super‐resolution microscopy (SRM) that restricts spatiotemporal resolution and observation time. Strategies for preventing or overcoming photobleaching in SRM are reviewed developing new probes and chemical environments. Photostabilization strategies are introduced first, which are borrowed from conventional fluorescence microscopy, that are employed in SRM. SRM‐specific strategies are then highlighted that exploit the on–off transitions of fluorescence, which is the key mechanism for achieving super‐resolution, which are becoming new routes to address photobleaching in SRM. Off states can serve as a shelter from excitation by light or an exit to release a damaged probe and replace it with a fresh one. Such efforts in overcoming the photobleaching limits are anticipated to enhance resolution to molecular scales and to extend the observation time to physiological lifespans.